Uterine sarcomas account for 3% of uterine cancers. Uterine sarcomas comprise leiomyosarcoma, endometrial stromal sarcoma, adenosarcoma, undifferentiated endometrial sarcoma, and their variants. The rarity of these tumors has prevented the performance of large epidemiological studies to identify risk factors. Data regarding parity, onset of menarche, or age at menopause as risk factors are inconclusive. Myxoid leiomyosarcoma (MLMSs) is an uncommon tumor, in most cases recognized only after surgery. When MLMSs is associated with multiple myomata, the gross appearance of the malignant mass differs from others for a soft, necrotic and gelatinous aspect. In the past, the presence of 10 or more mitoses per 10 high-power fields (HPFs) was considered key to establish the diagnosis of leiomyosarcoma. Even though mitotic index is an important feature in the assessment of malignancy, several studies based on large series of uterine smooth muscle tumors (U-SMTs) have shown that mitotic activity alone is not predictive of poor outcome in these tumors.
Uterine Myxoid Leiomyosarcoma Associated with Multiple Myomas in a Fertile Woman: A Case Report
Last date updated on June, 2021